Clinical trial / 2024
Circulating xylitol was linked to 3-year MACE risk, and xylitol consumption enhanced platelet responsiveness in healthy volunteers.
In a discovery cohort of 1,157 patients undergoing elective diagnostic cardiac evaluations, circulating levels of a polyol tentatively assigned as xylitol were associated with incident 3-year MACE risk. In a validation cohort of 2,149 patients, xylitol was confirmed to associate with incident MACE risk (third vs. first tertile adjusted HR 1.57, 95% CI 1.12-2.21, P < .01). Complementary mechanistic assays indicated xylitol enhanced platelet reactivity and in vivo thrombosis. Furthermore, an intervention in 10 healthy volunteers showed that consuming a xylitol-sweetened drink markedly raised plasma levels and enhanced multiple measures of platelet responsiveness in all subjects.
- Study type
- Cohort studies, mechanistic experiments, and an intervention trial
- Who was studied
- 1,157 discovery and 2,149 validation cardiac patients; 10 healthy volunteers
- What was measured
- Incident 3-year major adverse cardiovascular events (MACE) and platelet function
THE PAPER
Xylitol is prothrombotic and associated with cardiovascular risk.
Witkowski M, Nemet I, Li XS, Wilcox J, Ferrell M, Alamri H, Gupta N, Wang Z, Tang WHW, Hazen SL. Eur Heart J, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.